Coronavirus infection (SARS-CoV-2) in obesity and diabetes comorbidities: is heat shock response determinant for the disease complications?

Krause, Maurício; Gerchman, Fernando; Friedman, Rogério

doi:10.1186/s13098-020-00572-w

Cited by 33 publications

(35 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rather, obese patients have a larger amount of ACE2expressing adipose tissue in the body which indirectly results in an increased amount of ACE2-expressing cells (93). Other factors put forward to explain COVID-19 severity in obese individuals include abnormal cytokine and complement production leading to the reduction in the activity processes that inhibits acute inflammation (94,95). Increased risk of blood clotting due to obesity has also been proposed to play a role (95,96).…”

Section: Discussionmentioning

confidence: 99%

Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis

Tipih

Aminake

et al. 2021

mBio

258

175

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the globe at unprecedented speed and is showing no signs of slowing down. The outbreak of coronavirus disease 2019 (COVID-19) has led to significant health burden in infected patients especially in those with underlying comorbidities. The aim of this study was to evaluate the correlation between comorbidities and their role in the exacerbation of disease in COVID-19 patients leading to fatal outcomes. A systematic review was conducted using data from MEDLINE, Scopus, Web of Science, and EMBASE databases published from 1 December 2019 to 15 September 2020. Fifty-three articles were included in the systematic review. Of those 53 articles, 8 articles were eligible for meta-analysis. Hypertension, obesity, and diabetes mellitus were identified to be the most prevalent comorbidities in COVID-19 patients. Our meta-analysis showed that cancer, chronic kidney diseases, diabetes mellitus, and hypertension were independently associated with mortality in COVID-19 patients. Chronic kidney disease was statistically the most prominent comorbidity leading to death. However, despite having high prevalence, obesity was not associated with mortality in COVID-19 patients. IMPORTANCE COVID-19 has plagued the world since it was first identified in December 2019. Previous systematic reviews and meta-analysis were limited by various factors such as the usage of non-peer reviewed data and were also limited by the lack of clinical data on a global scale. Comorbidities are frequently cited as risk factors for severe COVID-19 outcomes. However, the degree to which specific comorbidities impact the disease is debatable. Our study selection involves a global reach and covers all comorbidities that were reported to be involved in the exacerbation of COVID-19 leading to fatal outcomes, which allows us to identify the specific comorbidities that have higher risk in patients. The study highlights COVID-19 high-risk groups. However, further research should focus on the status of comorbidities and prognosis in COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis

Tipih

Aminake

et al. 2021

mBio

258

175

View full text Add to dashboard Cite

show abstract

“…Proposed mechanisms linking obesity with COVID‐19 severity have been discussed in different reviews 7–9,53,63 . Increased inflammation with abnormal cytokine production is one of the most cited mechanisms, as well as abnormal complement production and a possible reduction in the activity of processes that inhibit acute inflammation 7,63 . An increased risk of thrombosis likely plays a role as well 7,8 .…”

Section: Obesity and Covid‐19: Proposed Mechanismsmentioning

confidence: 99%

Obesity and COVID‐19 in Latin America: A tragedy of two pandemics—Official document of the Latin American Federation of Obesity Societies

et al. 2020

Self Cite

View full text Add to dashboard Cite

Summary In May 2020, Latin America became the epicenter of the COVID‐19 pandemic, a region already afflicted by social disparities, poor healthcare access, inadequate nutrition and a large prevalence of noncommunicable chronic diseases. Obesity and its comorbidities are increasingly prevalent in Latin America, with a more rapid growth in individuals with lower income, and currently a disease associated with COVID‐19 severity, complications and death. In this document, the Latin American Association of Obesity Societies and collaborators present a review of the burden of two pandemics in Latin America, discuss possible mechanisms that explain their relationship with each other and provide public health and individual recommendations, as well as questions for future studies.

show abstract

“…Thus NF-κB signalling triggers a severe inflammatory response. Moreover the downstream products of NF-κB signalling such as iNOS and Nitric oxide block insulin signalling leading to worsening of the metabolic state (Krause et al 2020 ). There was a study conducted on mice which showed the association of insulin resistance with NF-κB activation via NIK (NF-κB inhibitory kinase) (Malle et al 2015 ).…”

Section: Introductionmentioning

confidence: 99%

The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients

et al. 2020

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) pandemic has affected health care systems worldwide. Severe presentations of COVID-19 such as severe pneumonia and acute respiratory distress syndrome (ARDS) have been associated with the post-viral activation and release of cytokine/chemokines which leads to a “cytokine storm” causing inflammatory response and destruction, mainly affecting the lungs. COVID-19 activation of transcription factor, NF-kappa B (NF-κB) in various cells such as macrophages of lung, liver, kidney, central nervous system, gastrointestinal system and cardiovascular system leads to production of IL-1, IL-2, IL-6, IL-12, TNF-α, LT-α, LT-β, GM-CSF, and various chemokines. The sensitised NF-κB in elderly and in patients with metabolic syndrome makes this set of population susceptible to COVID-19 and their worse complications, including higher mortality. Immunomodulation at the level of NF-κB activation and inhibitors of NF-κB (IκB) degradation along with TNF-α inhibition will potentially result in a reduction in the cytokine storm and alleviate the severity of COVID-19. Inhibition of NF-κB pathway has a potential therapeutic role in alleviating the severe form of COVID-19.

show abstract

Coronavirus infection (SARS-CoV-2) in obesity and diabetes comorbidities: is heat shock response determinant for the disease complications?

Cited by 33 publications

References 57 publications

Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis

Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis

Obesity and COVID‐19 in Latin America: A tragedy of two pandemics—Official document of the Latin American Federation of Obesity Societies

The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients

Contact Info

Product

Resources

About